INS and type 1 diabetes mellitus: As neither effective antiviral drugs nor approved effective vaccination are currently available, major efforts are needed to treat the deleterious effects of SARS-CoV-2 infection, especially for patients at high risk to develop diabetes; T2D and T1D, obese patients with impaired insulin sensitivity or patients with a family history of auto-immunity.